Human Papillomavirus (HPV) Enfeksiyonu ve HPV aşısında güncel yaklaşımlar

İnsan papilloma virüsü (HPV-Human papillomavirus) en yaygın cinsel yolla bulaşan enfeksiyonlardan biridir. Servikal kanser başta olmak üzere anogenital ve orofarengeal kanserler dâhil birçok hastalığa HPV neden olmaktadır. Bu hastalıklardan birincil korunma profilaktik HPV aşı uy- gulamalarını içermektedir. Gardasil, Cervarix ve Gardasil 9 olmak üzere üç tip HPV aşısı bulunmaktadır. Dünya genelinde gelişmiş ülkeler dâhil birçok ülke HPV aşılarını ulusal aşılama programlarına dâhil etmeye de- vam etmektedir. Güncel kanıtlar servikal kanserlerin önlenmesi ve HPV aşılama oranlarının artırılmasına katkı sağlamaktadır. Bu derlemede HPV enfeksiyonu ve HPV aşısında güncel yaklaşımlara odaklanılması amaçlanmaktadır.

Human Papillomavirus (HPV) Infection and current approaches to HPV vaccine

Human papillomavirus (HPV) is one of the most common sexually transmitted infections. It causes many diseases, including various anogenital and oropharyngeal cancers, especially cervical cancer. Primary protection from HPV includes prophylactic vaccination. There are three type HPV vaccines including Gardasil, Cervarix and Gardasil 9. Around the world, including developed countries, countries have introduced the HPV vaccine into their National Immunization Programs. Current evidences have contributed to achieving the goal of increasing HPV vaccination rates in the prevention of cervical. The aim of this review to focus on current approaches in HPV infection and HPV vaccine

PDF

___

1. de Villiers E-M. Cross-roads in the classification of papillomaviruses. Virology. 2013;445(1-2):2–10. [CrossRef ]
2. Meites, E, Gee J, Unger E, Markowitz L. Epidemiology and prevention of vaccine-preventable diseases. Centers for Disease Control and Prevention. Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S. (eds.), Human Popillomavirus. 14th ed. Washington DC: Public Health Foundation; 2021. p. 165-178. https://www. cdc.gov/vaccines/pubs/pinkbook/downloads/hpv.pdf
3. Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11):660–4. [CrossRef ]
4. Winer RL, Hughes JP, Feng Q, Stern JE, Xi LF, Koutsky LA. Incident detection of high-risk human papillomavirus infections in a cohort of high-risk women aged 25-65 years. J Infect Dis. 2016;214(5):665–75. [CrossRef ]
5. Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383:1340–8. [CrossRef ]
6. Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2019;68(32):698–702. [CrossRef ]
7. T. C. Sağlık Bakanlığı, Türkiye Halk Sağlığı Kurumu Kanser Daire Başkanlığı. Türkiye Kanser Kontrol Programı. 1. Baskı. Ankara: 2016. 1–92. https://hsgm.saglik.gov.tr/depo/birimler/ kanser-db/yayinlar/Kitaplar/TURKIYE_KANSER_KONTROL_ PROGRAMI_2016.pdf
8. T.C. Sağlık Bakanlığı, Halk Sağlığı Genel Müdürlüğü Kanser Daire Başkanlığı. Serviks Kanseri Tarama Programı Ulusal Standartları. https://hsgm.saglik.gov.tr/tr/kanser-tarama- standartlari/listesi/serviks-kanseri-tarama-program%C4%B1- ulusal-standartlar%C4%B1.html
9. International Human Papillomavirus Reference Center. HPV Reference clones, Stockholm: Karolinska Institutet (updated 2021 Sept 06). https://www.hpvcenter.se/human_reference_clones/
10. Skoulakis A, Fountas S, Mantzana-Peteinelli, M. Pantelidi K. Petinaki E. Prevalence of human papillomavirus and subtype distribution in male partners of women with cervical intraepithelial neoplasia (CIN): a systematic review. BMC Infect Dis. 2019;19(1):2–11. [CrossRef ]
11. Bruni L, Albero G, Serrano B, Mena M, Gómez D, et al. ICO/ IARC Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases in Turkey. Summary report 22 October 2021. https://hpvcentre.net/statistics/ reports/TUR.pdf?t=1566212891661
12. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. [CrossRef ]
13. Bora Başara B, Aygün A, Soytutan Çağlar İ, Kulali B. Sağlık İstatistikleri Yıllığı 2020 Haber Bülteni. Sağlık Bilgi Sistemleri Genel Müdürlüğü. Sağlık Bakanlığı. Ankara: 2021. https://sbsgm. saglik.gov.tr/Eklenti/41611/0/haber-bulteni-2020pdf.pdf
14. Sahin S, Akalin A. Adölesanlarda Üreme Sağlığı ve Cinsel Sağlık. Çinar N, Cabar HD, editörler. Adölesan Sağlığını Koruma ve Geliştirme. Ankara: Akademisyen Kitabevi; 2021. p. 181–94.
15. Gultekin M, Zayifoglu Karaca M, Kucukyildiz I, Dundar S, Keskinkilic B, Turkyilmaz M. Mega Hpv laboratories for cervical cancer control: Challenges and recommendations from a case study of Turkey. Papillomavirus Res. 2019;7:118–22. [CrossRef ]
16. Hacettepe Üniversitesi Nüfus Etütleri Enstitüsü. 2018 Türkiye Nüfus ve Sağlık Araştırması. Hacettepe Üniversitesi Nüfus Etütleri Enstitüsü, T. C. Cumhurbaşkanlığı Strateji ve Bütçe Başkanlığı ve TÜBİTAK, Ankara; 2019. http://www.hips.hacettepe.edu.tr/ tr/2018_turkiye_nufus_ve_saglik_arastirmasi-55
17. World Health Organization. Human papillomavirus (HPV) and cervical cancer. 2019a. https://www.who.int/news-room/fact- sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer
18. Akalin A, Pinar G. Unmet needs of women diagnosed with gynecologic cancer: An overview of literature. J Palliat Care Med. 2016;6:249. [CrossRef ]
19. Santhanes D, Yong CP, Yap YY, Saw PS, Chaiyakunapruk N, Khan TM. Factors influencing intention to obtain the HPV vaccine in South East Asian and Western Pacific regions: A systematic review and meta-analysis. Sci Rep. 2018;8(1):3–11. [CrossRef ]
20. López N, Garcés-Sánchez M, Panizo MB, de la Cueva IS, Artés MT, Ramos B, et al. HPV knowledge and vaccine acceptance among European adolescents and their parents: A systematic literature review. Public Health Rev. 2020;41:10. [CrossRef ]
21. WHO guideline for screening and treatment of cervical pre- cancer lesions for cervical cancer prevention, second edition. Geneva: World Health Organization; 2021. https://www.who.int/ publications/i/item/9789240014107
22. Food and Drug Administration. Prescribing information [package insert]. Gardasil (human papillomavirus quadrivalent [types 6, 11, 16, and 18] vaccine, recombinant). Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2015. https://www.fda.gov/media/74350/ download
23. Food and Drug Administration. Prescribing information [package insert]. Cervarix (human papillomavirus bivalent [types 16 and 18] vaccine, recombinant). Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2016. https://www.fda.gov/media/78013/download
24. Food and Drug Administration. Prescribing information [package insert]. Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant). Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2018. https:// www.fda.gov/media/90064/download
25. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent Human Papillomavirus Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56:1–24. [CrossRef ]
26. Centers for Disease Control and Prevention (CDC). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(20):630–2. https://www.cdc.gov/mmwr/preview/ mmwrhtml/mm5920a5.htm
27. Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(20):626–9. https:// www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a4.htm
28. Food and Drug Administration. December 10, 2014 Approval letter -GARDASIL 9. Silver Spring, MD. US Department of Health and Human Services. Food and Drug Administration; 2014. https://www.accessdata.fda.gov/drugsatfda_docs/ nda/2014/125554Orig1s000Approv.pdf
29. Petrosky E, Bocchini JA, Hariri S, Chesson H, Curtis CR, Saraiya M, et al. Use of 9-valent human papillomavirus (hpv) vaccine: updated hpv vaccination recommendations of the advisory committee on immunization practices. Morb Mortal Wkly Rep. 2015;64:300–4. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6411a3.htm
30. Center for Disease Control and Prevention 2020. Charter of the Advisory Committee on Immunization Practices https://www.cdc. gov/vaccines/acip/committee/acip-charter.pdf
31. Centers for Disease Control and Prevention. HPV Vaccination Recommendations. https://www.cdc.gov/vaccines/vpd/hpv/hcp/ recommendations.html
32. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63:1–30. https://www. cdc.gov/mmwr/preview/mmwrhtml/rr6305a1.htm
33. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination-updated recommendations of the advisory committee on immunization. MMWR Morb Mortal Wkly Rep. 2016;65(49):1405–8. [CrossRef ]
34. World Health Organization, Guide to introducing HPV vaccine into national immunization programmes. Geneva, Switzerland: World Health Organisation; 2016. https://apps.who.int/ iris/bitstream/handle/10665/253123/9789241549769-eng. pdf?sequence=1&isAllowed=y
35. World Health Organization, Major milestone reached as 100 countries have introduced HPV vaccine into national schedule. 2019. https://www.who.int/news/item/31-10-2019-major- milestone-reached-as-100-countries-have-introduced-hpv- vaccine-into-national-schedule
36. Türkiye İlaç ve Tıbbi Cihaz Kurumu. Ruhsatlı ürünler listesi. 2022. https://www.titck.gov.tr/dinamikmodul/85 37. Türk İlaç Rehberi. Gardasil Kuadivalan Human Papillomavirus (Tip 6. 11. 16. 18) Rekombinant aşısı 2021 Fiyat Bilgileri. https://www. ilacrehberi.com/v/gardasil-kuadivalan-humanpapillomavirus-tip- 6-11-b0f8/ilac-fiyati-2021/
38. Turkey Ministry of Health. 2020 Childhood vaccination schedule, Turkey; 2020. https://asi.saglik.gov.tr/asi-takvimi/
39. Donmez S, Ozturk R, Kısa S, Weller BK, Zeyneloglu S. Knowledge and perception of female nursing students about human papillomavirus (HPV), cervical cancer, and attitudes toward HPV vaccination. J Am Coll Health. 2019;67(5):410–7. [CrossRef ]
40. Guvenc G, Seven M, Akyuz A. Health belief model scale for human papilloma virus and its vaccination: adaptation and psychometric testing. J Pediatr Adolesc Gynecol. 2016;29(3):252–8. [CrossRef ]
41. Yoruk S, Açikgoz A, Ergor G. Determination of knowledge levels, attitude and behaviors of female university students concerning cervical cancer. Human Papiloma Virus and its vaccine. BMC Womens Health. 2016;16:51. [CrossRef ]
42. Falik RB, Albrecht SA, Cassidy BL. Policy support for expanding the adolescent vaccine school mandate in Pennsylvania to include the human papillomavirus (HPV) vaccine. J Am Assoc Nurse. 2019;31(4):263–8. [CrossRef ]
43. Mascaro V, Pileggi C, Currà A, Bianco A, Pavia M. HPV vaccination coverage and willingness to be vaccinated among 18-30 year-old students in Italy. Vaccine. 2019;37(25):3310–6. [CrossRef ]
44. Natipagon-Shah B, Lee E, Lee S. Knowledge, beliefs, and practices among U. S. college students concerning papillomavirus vaccination. J. Community Health. 2021;46(2):380–8. [CrossRef ]
45. Phillips A, Patel C, Pillsbury A, Brotherton J, Macartney K. Safety of human papillomavirus vaccines: an updated review. Drug Saf. 2018;41(4):329–46. [CrossRef ]
46. World Health Organization. Meeting of the global advisory committee on vaccine safety. 7-8 June 2017. Wkly Epidemiol Rec. 2017;92(28):393–404. https://www.who.int/publications/i/item/ WER9228
47. National Cancer Institute. Human Papillomavirus (HPV) Vaccines. Updated May 2021. https://www.cancer.gov/about-cancer/causes- prevention/risk/infectious-agents/hpv-vaccine-fact-sheet#content
48. Shimabukuro TT, Su JR, Marquez PL, Mba-Jonas A, Arana JE, Cano MV. Safety of the 9-valent human papillomavirus vaccine. Pediatrics. 2019;144(6):e20191791. [CrossRef ]
49. Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;5(5):CD009069. [CrossRef ]
50. Fontham ETH, Wolf AM, Church TR, Etzioni R, Flowers CR, Herzig A, et al. Cervical cancer screening for individuals at average risk:2020 guidelines update from the American Cancer Society. CA Cancer J Clin. 2020;70(5):321–46. [CrossRef ]